March 29, 2012
Astellas Pharma announced on March 27 that its European subsidiary Astellas Pharma Europe has filed a market authorization application (MAA) in Europe for EC905, a fixed-dose combination tablet for the treatment of overactive bladder Vesicare (solifenasin) and the treatment of...read more